Clinical Trial Update: Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating low-dose conditioning followed by donor stem cell transplantation for severe systemic sclerosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Snippet

Sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | Conditions: Systemic Scleroderma | Phase 2 | Status: WITHDRAWN